» Articles » PMID: 11847277

Structural Insights into Human Serum Albumin-mediated Prostaglandin Catalysis

Overview
Journal Protein Sci
Specialty Biochemistry
Date 2002 Feb 16
PMID 11847277
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have shown that many arachidonic acid metabolites bind to human serum albumin (HSA) and that the metabolism of these molecules is altered as a result of binding. The present study attempted to gain insights into the mechanisms by which prostaglandins bound to subdomain 2A of HSA are metabolized by catalytic processes. The breakdown of the prostaglandin 15-keto-PGE(2) to 15-keto-PGA(2) and 15-keto-PGB(2) in the presence of wild-type HSA and a number of subdomain 2A mutants was examined using a previously validated spectroscopic method which monitors absorbance at 505 nm. The species examined using this method were wild-type HSA, K195M, K199M, F211V, W214L, R218M, R218P, R218H, R222M, H242V, R257M, and bovine serum albumin. Previous studies of HSA-mediated catalysis indicated that the breakdown of HSA-bound prostaglandins results from an alkaline microenvironment in the binding site. Our results show that the catalytic breakdown of HSA-bound 15-keto-PGE(2) to 15-keto-PGB(2) results from two specific processes which are modulated by specific amino acid residues. Specifically, some amino acid residues modulate the rate of step 1, the conversion of 15-keto-PGE(2) to 15-keto-PGA(2), while other residues modulate the rate of step 2, the conversion of 15-keto-PGA(2) to 15-keto-PGB(2). Some residues modulate the rate of steps 1 and 2. In total, while our results support the involvement of certain basic amino acid residues in the catabolism of HSA-bound 15-keto-PGE(2), our data suggest that metabolism of HSA-bound prostaglandins may be a more complex and specific process than previously thought.

Citing Articles

Baseline (modified) Glasgow prognostic score as a predictor of therapeutic response to immune checkpoint inhibitors in solid tumors: A systematic review and meta‑analysis.

Ye H, Li M Oncol Lett. 2025; 29(4):184.

PMID: 40007624 PMC: 11851447. DOI: 10.3892/ol.2025.14931.


The impact of trauma relevant concentrations of prostaglandin E on the anti-microbial activity of the innate immune system.

Nicholson T, Belli A, Lord J, Hazeldine J Front Immunol. 2024; 15:1401185.

PMID: 39502706 PMC: 11535544. DOI: 10.3389/fimmu.2024.1401185.


High-resolution ion mobility spectrometry-mass spectrometry for isomeric separation of prostanoids after Girard's reagent T derivatization.

Lamont L, Hadavi D, Bowman A, Flinders B, Cooper-Shepherd D, Palmer M Rapid Commun Mass Spectrom. 2022; 37(5):e9439.

PMID: 36415963 PMC: 10078546. DOI: 10.1002/rcm.9439.


The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.

Kasajima M, Igawa S, Manaka H, Yamada K, Akazawa Y, Manabe H Oncology. 2022; 101(1):69-76.

PMID: 36103811 PMC: 9872847. DOI: 10.1159/000526964.


Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease.

Tufoni M, Baldassarre M, Zaccherini G, Antognoli A, Caraceni P Curr Hepatol Rep. 2020; 19(3):147-158.

PMID: 32837825 PMC: 7326530. DOI: 10.1007/s11901-020-00521-1.


References
1.
PETERSEN C, Ha C, Harohalli K, Park D, Bhagavan N . Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. Chem Biol Interact. 2000; 124(3):161-72. DOI: 10.1016/s0009-2797(99)00143-x. View

2.
Dockal M, Carter D, Ruker F . The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999; 274(41):29303-10. DOI: 10.1074/jbc.274.41.29303. View

3.
Dockal M, Chang M, Carter D, Ruker F . Five recombinant fragments of human serum albumin-tools for the characterization of the warfarin binding site. Protein Sci. 2000; 9(8):1455-65. PMC: 2144726. DOI: 10.1110/ps.9.8.1455. View

4.
Petitpas I, Bhattacharya A, Twine S, East M, Curry S . Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem. 2001; 276(25):22804-9. DOI: 10.1074/jbc.M100575200. View

5.
Unger W . Binding of prostaglandin to human serum albumin. J Pharm Pharmacol. 1972; 24(6):470-7. DOI: 10.1111/j.2042-7158.1972.tb09034.x. View